CII 259-273
Type II collagen peptide 259-273
15 Amino Acids · MW: ≈1.6 kDa
Amino Acids
15
Molecular Weight
≈1.6 kDa
Half-life
≈1-2 h
Research Score
3.9
Studies
74
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is CII 259-273?
An immunodominant collagen II epitope used in experimental and translational rheumatoid arthritis tolerance strategies. It is designed to retrain the immune system against joint-specific autoantigen rather than suppressing immunity broadly.
Key Benefits & Mechanisms
joint-antigen tolerance
RA model suppression
autoantigen-specific therapy
Research Summary
CII 259-273 is a real collagen II autoantigen peptide widely used in RA research and peptide-tolerance studies. It is better established as a research/tolerization epitope than as an approved medicine.
Related Peptides
P140
Phosphorylated U1-70K-derived peptide (Lupuzor)
A synthetic phosphopeptide from the spliceosomal U1-70K protein studied as an immune-tolerizing therapy for systemic lupus erythematosus. It aims to restore antigen-specific tolerance rather than broadly suppress immunity.
AutoimmunehCDR1
Human complementarity-determining region 1 peptide (Edratide)
A synthetic 19-mer derived from a human anti-DNA antibody sequence and developed as an immunomodulatory peptide for SLE. It has been studied for dampening pathogenic anti-dsDNA responses and restoring immune balance.
AutoimmunednaJP1
dnaJ heat-shock protein 70-derived peptide
A synthetic peptide derived from the bacterial dnaJ/heat-shock protein family that was evaluated as an antigen-specific therapy in rheumatoid arthritis. The concept is to induce regulatory immune responses to shared heat-shock protein epitopes.
Autoimmunep277
Heat shock protein 60-derived peptide p277 (DiaPep277)
A 24-amino-acid HSP60-derived peptide developed to promote immune tolerance and reduce inflammatory autoimmunity. It has been most visible in type 1 diabetes research, but it is a bona fide peptide immunomodulator in the autoimmune space.
Autoimmune